Making use of the primary tumour

被引:8
作者
Baars, A [1 ]
Buter, J [1 ]
Pinedo, HM [1 ]
机构
[1] Vrije Univ Amsterdam, Dept Med Oncol, Med Ctr, NL-1007 MB Amsterdam, Netherlands
关键词
D O I
10.1002/bies.10194
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Surgical resection of a primary tumour is often not sufficient to cure a patient. Even when no residual cancer can be detected at time of surgery, metastases may appear in the following years, which indicates that the primary tumour had apparently spread before surgery. Following surgery, systemic chemotherapy may be used to eradicate micro-metastatic disease. Here we present two unconventional strategies that implement new insights into tumour biology and tumour immunology in the treatment of patients with cancer. Both experimental strategies use the individual characteristics of the patient's primary tumour to optimise the control of life-threatening micro-metastases. We aim to modulate the patient's adaptive immune system, targeting it towards the patient's own tumour cells to eradicate residual disease following local treatment. In one approach, this is done by autologous tumour cell vaccinations as adjuvant treatment for colon cancer patients and, in a second approach, by giving chemo-imunotherapy before local treatment to women with locally advanced breast cancer.
引用
收藏
页码:79 / 86
页数:8
相关论文
共 27 条
[1]   Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor [J].
Armitage, JO .
BLOOD, 1998, 92 (12) :4491-4508
[2]  
COLEY WB, 1893, CLIN ORTHOP RELAT R, P3
[3]   Biological therapy of colorectal cancer [J].
de Kleijn, EMHA ;
Punt, CJA .
EUROPEAN JOURNAL OF CANCER, 2002, 38 (07) :1016-1022
[4]  
Esteva, 1998, Oncologist, V3, P300
[5]   Cancer vaccines [J].
Greten, TF ;
Jaffee, EM .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (03) :1047-1060
[6]   Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group study E5283 [J].
Harris, JE ;
Ryan, L ;
Hoover, HC ;
Stuart, RK ;
Oken, MM ;
Benson, AB ;
Mansour, E ;
Haller, DG ;
Manola, J ;
Hanna, MG .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (01) :148-157
[7]   Cross-presentation, dendrttic cells, tolerance and immunity [J].
Heath, WR ;
Carbone, FR .
ANNUAL REVIEW OF IMMUNOLOGY, 2001, 19 :47-64
[8]  
Honkoop A H, 1999, Oncologist, V4, P106
[9]  
HOOVER HC, 1984, CANCER RES, V44, P1671
[10]   ADJUVANT ACTIVE SPECIFIC IMMUNOTHERAPY FOR HUMAN COLORECTAL-CANCER - 6.5-YEAR MEDIAN FOLLOW-UP OF A PHASE-III PROSPECTIVELY RANDOMIZED TRIAL [J].
HOOVER, HC ;
BRANDHORST, JS ;
PETERS, LC ;
SURDYKE, MG ;
TAKESHITA, Y ;
MADARIAGA, J ;
MUENZ, LR ;
HANNA, MG .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (03) :390-399